

# Diogo Mendes

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/9538308/diogo-mendes-publications-by-year.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

30  
papers

424  
citations

11  
h-index

20  
g-index

34  
ext. papers

544  
ext. citations

3  
avg, IF

4.06  
L-index

#	Paper	IF	Citations
30	Risk of Cardiovascular and Venous Thromboembolic Events Associated With Janus Kinase Inhibitors in Rheumatoid Arthritis: A Systematic Review and Network Meta-analysis. <i>Journal of Clinical Rheumatology</i> , <b>2021</b> , 28,	1.1	2
29	Real-world intensive safety monitoring of biosimilars rituximab and trastuzumab in a Portuguese oncology hospital. <i>Journal of Oncology Pharmacy Practice</i> , <b>2021</b> , 27, 1432-1438	1.7	3
28	The Risk of Infections Associated With JAK Inhibitors in Rheumatoid Arthritis: A Systematic Review and Network Meta-analysis. <i>Journal of Clinical Rheumatology</i> , <b>2021</b> ,	1.1	4
27	Rectus sheath hematoma in patients receiving subcutaneous enoxaparin: A case series of five patients. <i>Clinical Case Reports (discontinued)</i> , <b>2020</b> , 8, 3432-3439	0.7	3
26	Spontaneous reports of hypersensitivity adverse drug reactions in Portugal: a retrospective analysis. <i>Expert Opinion on Drug Safety</i> , <b>2020</b> , 19, 763-769	4.1	1
25	Risk of infections and cardiovascular and venous thromboembolic events associated with JAK inhibitors in rheumatoid arthritis: protocols of two systematic reviews and network meta-analyses. <i>BMJ Open</i> , <b>2020</b> , 10, e041420	3	3
24	A Systematic Review of Economic Studies Evaluating Ophthalmic Drugs: An Analysis of the Health-state Utilities. <i>Ophthalmic Epidemiology</i> , <b>2020</b> , 27, 325-338	1.9	
23	Outcomes From the First 6 Years of Operation of the Central Portugal Pharmacovigilance Unit. <i>Journal of Patient Safety</i> , <b>2020</b> , 16, e136-e142	1.9	1
22	Intensive safety monitoring program of antineoplastic medicines: A pilot study in a Portuguese oncology hospital. <i>Journal of Oncology Pharmacy Practice</i> , <b>2020</b> , 26, 133-140	1.7	1
21	Prevalence of Undiagnosed Hypothyroidism in Europe: A Systematic Review and Meta-Analysis. <i>European Thyroid Journal</i> , <b>2019</b> , 8, 130-143	4.2	22
20	Drug-induced hypersensitivity: A 5-year retrospective study in a hospital electronic health records database. <i>Journal of Clinical Pharmacy and Therapeutics</i> , <b>2019</b> , 44, 54-61	2.2	4
19	Fluoroquinolones and the risk of tendon injury: a systematic review and meta-analysis. <i>European Journal of Clinical Pharmacology</i> , <b>2019</b> , 75, 1431-1443	2.8	33
18	Effectiveness in clinical practice versus efficacy of dipeptidyl peptidase-4 inhibitors in clinical trials for type 2 diabetes: protocol for systematic review. <i>BMJ Open</i> , <b>2019</b> , 9, e032522	3	
17	Statins and risk of cataracts: A systematic review and meta-analysis of observational studies. <i>Cardiovascular Therapeutics</i> , <b>2018</b> , 36, e12480	3.3	7
16	Number needed to treat (NNT) in clinical literature: an appraisal. <i>BMC Medicine</i> , <b>2017</b> , 15, 112	11.4	60
15	The Use of the Number Needed to Treat (NNT) to Assess the Effects of Medicinal Interventions: A Quality Assessment. <i>Clinical Therapeutics</i> , <b>2017</b> , 39, e39-e40	3.5	
14	Risk of Ophthalmic Adverse Effects in Patients Treated with MEK Inhibitors: A Systematic Review and Meta-Analysis. <i>Ophthalmic Research</i> , <b>2017</b> , 57, 60-69	2.9	10

13	Benefit-Risk of Therapies for Relapsing-Remitting Multiple Sclerosis: Testing the Number Needed to Treat to Benefit (NNTB), Number Needed to Treat to Harm (NNTH) and the Likelihood to be Helped or Harmed (LHH): A Systematic Review and Meta-Analysis. <i>CNS Drugs</i> , <b>2016</b> , 30, 909-29	6.7	19
12	A systematic review and meta-analysis of the association between systemic fluoroquinolones and retinal detachment. <i>Acta Ophthalmologica</i> , <b>2016</b> , 94, e251-9	3.7	13
11	A systematic review of observational studies evaluating costs of adverse drug reactions. <i>ClinicoEconomics and Outcomes Research</i> , <b>2016</b> , 8, 413-26	1.7	24
10	Testing the usefulness of the number needed to treat to be harmed (NNTH) in benefit-risk evaluations: case study with medicines withdrawn from the European market due to safety reasons. <i>Expert Opinion on Drug Safety</i> , <b>2016</b> , 15, 1301-12	4.1	9
9	Drug-induced ocular adverse reactions: review of the safety alerts issued during the last decade. <i>Journal of Ocular Pharmacology and Therapeutics</i> , <b>2015</b> , 31, 258-68	2.6	10
8	Number needed to harm in the post-marketing safety evaluation: results for rosiglitazone and pioglitazone. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2015</b> , 24, 1259-70	2.6	19
7	Farmacovigilância em Portugal: Atividade da Unidade Regional do Centro. <i>Acta Medica Portuguesa</i> , <b>2015</b> , 28, 222	1.4	7
6	The benefit of HER2-targeted therapies on overall survival of patients with metastatic HER2-positive breast cancer--a systematic review. <i>Breast Cancer Research</i> , <b>2015</b> , 17, 140	8.3	114
5	Safety profiles of adalimumab, etanercept and infliximab: a pharmacovigilance study using a measure of disproportionality in a database of spontaneously reported adverse events. <i>Journal of Clinical Pharmacy and Therapeutics</i> , <b>2014</b> , 39, 307-13	2.2	15
4	The Benefit of Her-2 Targeted Therapies on Overall Survival of Patients With Metastatic Breast Cancer - A Systematic Review. <i>Value in Health</i> , <b>2014</b> , 17, A620	3.3	1
3	NursesVsponaneous reporting of adverse drug reactions: expert review of routine reports. <i>Journal of Nursing Management</i> , <b>2014</b> , 22, 322-30	4.9	14
2	Safety monitoring of ophthalmic biologics: a systematic review of pre- and postmarketing safety data. <i>Journal of Ocular Pharmacology and Therapeutics</i> , <b>2014</b> , 30, 729-51	2.6	15
1	Safety of biologics approved for treating rheumatoid arthritis: analysis of spontaneous reports of adverse events. <i>Clinical Rheumatology</i> , <b>2013</b> , 32, 1207-14	3.9	9